logo
Why Covid cases are rising, why you needn't worry

Why Covid cases are rising, why you needn't worry

Indian Express28-05-2025

The Health Ministry this week said fresh cases of Covid-19 have been seen mainly in Maharashtra, Karnataka, Tamil Nadu, and Kerala, and that a new subvariant, NB.1.8.1, had been detected in at least one sample.
This sample, which was collected and sequenced in April, was submitted to INSACOG, India's Covid-19 genome sequencing consortium, from Tamil Nadu.
Several countries are reporting Covid-19 surges; World Health Organisation (WHO) data show noticeable increases in South-East Asia. On May 13, Singapore reported a rise from 11,100 cases during April 20-26 to 14,200 during April 27-May 3.
What is the current situation in India?
There were 1,010 active infections as of Tuesday evening, according to data on the Health Ministry's Covid-19 dashboard. The largest number of cases (43%) were in Kerala, followed by Maharashtra (21%). Delhi, Gujarat, and Tamil Nadu had 10%, 8%, and 7% of cases.
Since May 19, deaths have been reported in Maharashtra (3), Kerala (2), and Karnataka (1). However, the Ministry has said 'more details are awaited' before these deaths can be attributed to Covid-19.
The outbreak seems to be geographically limited. The numbers of active cases were in double digits in only nine states on Tuesday, and only Kerala, Maharashtra, and Delhi had more than 100 cases each.
However, a clearer picture is expected to emerge over the next fortnight, as testing of symptomatic individuals increases.
Official data on hospitalisation are not yet available. But large hospital chains have not reported any significant increase in Covid-19-related admissions. The few patients who have been admitted mostly have pre-existing comorbidities — which suggests that new cases are not, as of now, leading to severe disease.
What is triggering the increase in cases?
While reporting their surge on May 13, the Singaporean health authorities pointed out that periodic waves of Covid-19 — like other endemic respiratory diseases — were expected throughout the year.
SARS-CoV-2, the virus responsible for Covid-19, has not disappeared, but it no longer behaves like an unpredictable emergency — rather, it has become part of a recurring cycle of illnesses, similar to the flu. Several factors could be contributing to the rise in cases:
Which new variants have emerged, and which one is currently widespread?
Three categories of variants are closely monitored.
JN.1 accounted for 16.3% of sequenced cases in the epidemiological week that ended on February 2. Singaporean authorities have reported that two JN.1 descendant lineages — LF.7 and NB.1.8 — make up more than two-thirds of locally sequenced cases. However, they have clarified that 'there is no indication that the variants circulating locally are more transmissible or cause more severe disease compared to previously circulating variants.'
In India, the virus in most samples sequenced over the past couple of months has been identified as either BA.2 or JN.1. Health officials have said there is no indication that they are more transmissible or cause more severe disease compared to earlier variants.
What precautions should you take?
If you're in a crowded place, or have symptoms like a runny nose, sore throat, headache, or a fever, it's important to wear a mask. According to the 2023 AIIMS/ ICMR-COVID-19 National Task Force guidelines, people with mild symptoms should isolate at home.
At home, you should maintain physical distancing, wear a mask, and practice good hand hygiene. Mild cases can usually be managed with rest, fluids, and medicines for symptom relief.
Stay hydrated, monitor your temperature and oxygen levels (SpO2), and be in touch with your doctor. Do not use antibiotics unless there's a clear sign of a bacterial infection.
Seek immediate medical attention if you have trouble breathing, your oxygen level drops to 93% or lower, or if you have a high fever or severe cough lasting for longer than five days.
Those older than 60, or with heart disease, diabetes, a weakened immune system, tuberculosis, chronic lung, kidney, or liver disease, or obesity, or those who are unvaccinated should be extra cautious.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases
COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases

India.com

time12 minutes ago

  • India.com

COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases

COVID-19 Cases Rising In India Highlights: India is once again witnessing an unsettling rise in COVID-19 cases, with the number of active infections climbing to 4866, according to the Ministry of Health and Family Welfare's latest update as of 8:00 AM IST, June 5, 2025. Leading the current spike is Kerala pushing its active caseload to 1487, nearly half of the country's total. Meanwhile, West Bengal added 106 new cases, increasing its active tally to 538, while the national capital Delhi recorded 105 new infections, taking its active cases to 562. As per May 2025 classifications by the World Health Organization (WHO), subvariants LF.7 and NB.1.8.1 are categorized as Variants Under Monitoring, meaning they are not yet deemed as Variants of Concern or Variants of Interest. However, these strains are suspected to be contributing to the rising infections not just in India but also across China and other parts of Asia. Despite the emergence of new subvariants, the JN.1 strain remains the most dominant, accounting for a staggering 53% of all positive cases across the country. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), a case of NB.1.8.1 was detected in Tamil Nadu in April, while four cases of LF.7 were identified in Gujarat earlier this month. With the virus subtly shifting form and symptoms evolving, health authorities are urging the public to maintain precautionary measures, including hygiene, mask use in crowded places, and timely testing. Although hospitalisation remains low, experts warn that complacency could reverse progress. Stay informed, and if you're experiencing mild symptoms like fatigue, a sore throat, or gastrointestinal discomfort, it's best to test early and isolate to prevent further spread.

A common drug shows promise for patients with liver disease
A common drug shows promise for patients with liver disease

Time of India

time15 minutes ago

  • Time of India

A common drug shows promise for patients with liver disease

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study, involving 154 participants, demonstrated significant improvements in MASH and fibrosis among those receiving dapagliflozin compared to the placebo group, suggesting a potential new treatment avenue. Liver disease accounts for two million deaths annually. This is 4% of all deaths (1 out of every 25 deaths worldwide), as per the data from 2023. Liver disease is a growing global health concern. A new study suggests that a widely used diabetes medication may offer hope for patients suffering from progressive liver disease. A recent clinical trial conducted in China and published in The BMJ suggests that the type 2 diabetes drug dapagliflozin can help patients with severe liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, which have limited treatment options. What does the diabetes drug do (Pic courtesy: iStock) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, which is widely used to treat type 2 diabetes, has been shown to improve progressive liver disease. The Chinese researchers found that the drug improved metabolic dysfunction-associated steatohepatitis (MASH), a condition where excess fat accumulates in the liver, leading to inflammation and liver fibrosis (a buildup of scar tissue). MASH affects more than 5% of adults, and it is also common (30%) in people with diabetes or obesity. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo This can progress to cirrhosis in up to 25% of individuals. Though previous studies have suggested that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, no trial has been carried out in patients with MASH. The study To understand the effects of dapagliflozin in patients with MASH, the researchers conducted a study. The 48-week study had 154 participants, who were diagnosed with MASH following liver biopsies at six Chinese medical centers from November 2018 to March 2023. Participants had an average age of 35, and 85% were men. Nearly half (45%0 had type 2 diabetes, and most had evidence of liver fibrosis at various stages (33% stage 1, 45% stage 2, 19% stage 3). Following an initial screening biopsy, the participants were randomly assigned to receive 10 mg of dapagliflozin or a matching placebo once daily for 48 weeks. They attended health education sessions twice a year. The researchers also recorded body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids of the participants throughout the trial. MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less. By the end of the study, which is after 48 weeks, the researchers observed that 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group. 23% (18 of 78) participants in the dapagliflozin group showed resolution of MASH without worsening of fibrosis, compared with 8% (6 of 76) in the placebo group. Trump Health Scare: 'Cognitive Decline' Spotted? Political Adviser's BIG Warning Amid Dementia Claim They also saw improvement in fibrosis without worsening of MASH in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group. 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group discontinued the treatment because of adverse events. What are the experts saying Fatty liver 'Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis,' they said. They added that large-scale and long-term trials are needed to further confirm these effects. The trial was conducted in a Chinese population, which limits its broader generalisability. They also noted that with the emergence of more drugs, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. 'Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,' they concluded. One step to a healthier you—join Times Health+ Yoga and feel the change

TTD issues Covid alert in Tirumala
TTD issues Covid alert in Tirumala

New Indian Express

time27 minutes ago

  • New Indian Express

TTD issues Covid alert in Tirumala

TIRUMALA: The Tirumala Tirupati Devasthanams (TTD) has sounded a COVID-19 alert on Wednesday, urging both employees and visiting pilgrims to follow precautionary measures in view of rising cases. On Wednesday evening, the TTD administration issued an emergency circular to all department heads and staff, directing strict implementation of health and safety guidelines issued by the Director of Public Health and Family Welfare. The circular emphasised enhanced vigilance in high-traffic areas such as queue complexes, accommodation blocks, and other public spaces within the Tirumala temple premises. It also called for the immediate suspension of mass gatherings, including prayer meetings, parties, and social functions. Elderly individuals and pregnant women have been advised to take extra precautions in view of Covid resurgence.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store